Ivanhoe Mines and SES Networks Revolutionise Connectivity for Mining Industry in Congo
31.1.2018 10:55:00 EET | Business Wire | Press release
The Kamoa-Kakula Copper Project in the Democratic Republic of Congo (DRC) will benefit from reliable high-performance managed connectivity services delivered by SES Networks. The solution will be provided under an agreement with Ivanhoe Mines, a leading mineral exploration and development company, SES announced today.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180130006568/en/
Ivanhoe Mines and SES Networks Revolutionise Connectivity for Mining Industry in Congo (Photo: Business Wire)
The managed services and fibre-like connectivity from SES Networks will be powered by its O3b Medium Earth Orbit satellite fleet. It will enable operators on site to do video-conferencing with headquarters, use cloud-based applications to access and upload critical data, and improve overall productivity and safety.
“We employ leading-edge exploration and development technologies at our projects, and to make sure that these technologies are applied successfully, we need to get the right information to the right people at the right time,” said Steve Amos, Ivanhoe’s Head of Projects in the DRC. “We look forward to working with SES Networks to improve connectivity and communications at our mine sites in the DRC.”
“Ivanhoe Mines operates some of the most sophisticated mining operations in the world and demands leading-edge performance combined with state-of-the-art reliability,” said Carole Kamaitha, Vice President of Fixed Data Sales Africa at SES Networks. “The turnkey solution delivered via our unique infrastructure will enable the crew working at the Kamoa-Kakula site to leverage the latest applications, communicate effectively, and maximise their productivity.”
The Kamoa-Kakula mining project is the world’s largest undeveloped high-grade copper discovery. Located about 270 kilometres away from the provincial capital of Lubumbashi, the mine exploration covers a near-surface stratiform copper deposit with adjacent exploration areas within the Central African Copperbelt. The project is a joint venture between Ivanhoe Mines, Zijin Mining and the Government of the Democratic Republic of Congo.
Follow us on:
About SES
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
About Ivanhoe Mines
Ivanhoe Mines (TSX: IVN; OTCQX: IVPAF) is advancing three principal projects in Southern Africa: mine development at the Platreef platinum-palladium-gold-nickel-copper discovery on the Northern Limb of South Africa’s Bushveld Complex, mine development and exploration at the Kamoa-Kakula Copper Project, and upgrading at the historic, high-grade Kipushi zinc-copper-silver-germanium mine on the Central African Copperbelt in the DRC.
The combined Kamoa-Kakula Indicated Mineral Resources total approximately one billion tonnes grading 3.02% copper, containing 66 billion pounds of copper, and another 191 million tonnes of Inferred Resources at 2.37% copper, with a 1.4% copper cut-off grade. In August 2012, the DRC government granted mining licences to Ivanhoe Mines for the Kamoa-Kakula Project, with the mine development work beginning in July 2014 with construction of a box cut for the decline ramps for the planned Kansoko Sud Mine. The first development ore from Kansoko was brought to surface in July 2017. Development work on the ultra-high-grade Kakula Discovery began in June 2017, 10 kilometres south of the Kansoko Sud Mine. Ivanhoe estimates the potential for the ultimate mining rate at Kamoa-Kakula of at least 18 million tonnes a year, through a number of phased expansions. For further details, visit www.ivanhoemines.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180130006568/en/
Contact information
SES
Markus Payer
Corporate Communications & PR
Tel.
+352 710 725 500
Markus.Payer@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom